Historically, both the natural and synthetic trans-RAs have been used to treat cancers of the hemopoietic system, in particular leukemia, by targeting the nuclear receptor RAR-RXR system, however, the efficacy remains poor for solid tumors due to drug resistance, poor aqueous solubility, poor accessibility, and a short half-life [23]. Here, RARA is linked to cancer.